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Abstract
The ascending anxiety regarding antimicrobial resistance as well as the recalcitrant 
nature of biofilm-associated infections call for the development of alternative strategies 
to treat bacterial diseases. Nanoparticles have been considered as one of the emerging 
and promising platforms in this respect. Their unique physical and chemical properties 
may lead to fine-tuned interactions between them and bacteria. In this chapter, we aim 
to provide an overview on the use of nanoparticles as antimicrobial agents. Both anti-
bacterial and anti-biofilm activities of nanoparticles and their current approaches will be 
reviewed. The in vitro methods that are used to evaluate the potency of nanoparticles as 
antimicrobial agents will be discussed in detail.
Keywords: antibacterial agents, nanoparticles, antibacterial resistance (AMR), anti-biofilm 
agents, in vitro methods
1. Introduction
The term antimicrobial was derived from the Greek words anti (against), micro (little), and bios 
(life), and it refers to all agents that act against microorganisms. Thus, antimicrobials include 
agents that act against bacteria (antibacterial), viruses (antiviral), fungi ( antifungal), and pro-
tozoa (antiprotozoal). Among these, antibacterial agents are by far the most widely known 
and studied class of antimicrobials. Nowadays, the emergence of antimicrobial  resistance 
(AMR) among the microbial pathogens greatly increases the threat generated by bacterial 
infections. Drug-resistant bacteria lead to poor clinical outcomes increasing health care costs 
and mortality. In the US, the estimated health care costs associated with the  treatment of 
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 infectious diseases are annually more than 120 billion dollars, and further,  treatment of infec-
tions caused by resistant pathogens costs 5 billion dollars per year [1]. According to the US 
Center for Disease Control and Prevention (CDC), more than two million antibiotic-resistant 
infections occur every year in the US and they lead to 23,000 deaths [2]. In the European Union, 
antibiotic-resistant infections are responsible for 25,000 deaths every year [3]. Both Gram-
positive, especially methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococcus faecium (VRE), and drug-resistant Streptococcus pneumoniae, and Gram-negative 
bacteria, namely multidrug-resistant Acinetobacter baumannii (MRAB), carbapenem-resistant 
Enterobacteriaceae (CRE), and Pseudomonas aeruginosa, display resistance to multiple drugs and 
are of serious concern [4]. In addition, biofilm formation complicates treatment of various 
infections. Biofilm-related infections, such as chronic wounds and  urinary tract infections, 
pneumonia in cystic fibrosis patients, and infections related to the use of medical devices, 
comprise up to 80% of all human bacterial infections, and affect  millions of people resulting 
in up to 550,000 deaths every year [5–7]. The emergence of AMR has been mainly attributed 
to the inappropriate and excessive use of antimicrobials in humans and animals. In many 
countries, unregulated availability of antibiotics without prescription results in promotion 
of overuse [8]. Further, inappropriate prescription of antibiotics also contributes to the pro-
motion of resistant bacteria. The reports have shown that the diagnosis, choice of treatment 
agent, or duration of antibiotic therapy were incorrect in 30–50% of the cases [9], and 30–60% 
of antibiotics prescribed in intensive care units have been inappropriate or unnecessary [10]. 
Extensive agricultural usage of antibiotics in livestock as growth supplement is another rea-
son of excessive consumption of antibiotics by humans, through the intake of resistant bacte-
ria in the food supplies.
It is estimated that more than 70% of all pathogenic bacteria are resistant to at least one of 
the conventional antibiotics [11]. Antimicrobial resistance is acquired on both cellular and 
community levels [12]. Acquirement and dissemination of resistance genes is a process that 
occurs over time. Nevertheless, the evolution of bacterial resistance is substantially acceler-
ated by the dispensable use of antibiotics [13]. Further dissemination of resistance genes 
between  bacterial species has led to the emergence of multidrug-resistant (MDR) bacteria 
[14]. Community level of resistance is caused by biofilm formation [15]. However, when 
it comes to biofilms, the genetically transferable, conventional resistance mechanisms are 
not the leading cause of decreased antimicrobial susceptibility [7]. Bacterial biofilms are 
 structured  communities of bacteria embedded in a matrix of extracellular polymeric sub-
stances (EPS) that can be formed on variety of surfaces, such as tissues and medical devices 
[16]. Biofilm is a transient  phenotype that makes even sensitive bacteria without known 
genetic basis for resistance to display remarkably reduced susceptibility to antimicrobials 
and host immune responses [17]. Many factors contribute to the antimicrobial tolerance of 
biofilms. First,  biofilm matrix can restrict penetration of antibiotics and protects the cells 
from detrimental insults [18]. Secondly, biofilms comprise a heterogeneous population of 
cells that are in different physiological states due to decreasing oxygen and nutrient gradi-
ents existing between the surface and deeper  layers of biofilms. For example, cells located in 
the deepest part of the  biofilm tend to  display a slower growth rate and, therefore, are less 
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susceptible to  antibiotics that are  developed against dividing cells [19, 20]. Further, the non-
dividing, dormant  population of bacteria, referred also as persister cells, is in well-protected 
mode and highly tolerant  antibiotics. These cells survive even from prolonged antibiotic 
treatment and serve as  reservoirs for infections [21]. Consequently, biofilm bacteria can be 
up to 1000 times more tolerant to antimicrobial agents than planktonic cells of the same 
species [22].
Despite this, pharmaceutical companies have substantially declined investments in  antimicrobial 
drug discovery during the past few decades [23]. Antimicrobial drug discovery is not economi-
cally attractive, and regulatory requirements have become very challenging [3, 24]. The need of 
novel bactericidal agents has increased due to the emergence of multi-drug resistant bacterial 
strains and biofilm-associated infections. Consequently, attention has been especially devoted 
to emerging nanoparticle-based  materials in the field of antimicrobial therapies. In this chapter, 
the existing  nanoparticles as  antimicrobial means and the current in vitro test methods that will 
ease clinical translation of nanomaterials by establishing in vivo relevant data will be described 
and discussed.
2. Nanotechnology-based antibacterial therapies
Antibacterial applications of nanotechnology are gaining  importance to prevent the cata-
strophic consequences of antibiotic resistance. Nanotechnology can be implemented as pre-
ventives, diagnostics, drug carriers, and synergetics in the antibacterial therapies.
The unique properties of nanomaterials compared to its bulk form make them favourable 
for antibacterial therapies. Many inorganic and organic nanomaterials represent inher-
ent  antibacterial properties that are not expressed in their bulk form. Fast and sensitive 
 bacterial detection can be provided with nanoparticle-based approaches. Furthermore, 
 nanoparticles offer discrete advantages as antibacterial drug delivery systems. They can 
be designed as  targeted,  environmentally responsive, combinatorial delivery systems [25]. 
Another approach of nanomaterials for the antibacterial therapy is as vaccine that contains 
 nanoparticles as adjuvants or delivery vehicles, which provoke immune responses against 
bacterial infection. In the following parts in section 2.1 and 2.2, the existing nanotechnolo-
gies for the antibacterial delivery systems and inherently antibacterial nanoparticles will be 
discussed in detail.
2.1. Nanomaterials as antibacterial delivery systems
The existing disadvantages of conventional antibiotics can be solved to some extent by using 
nanomaterial-based antimicrobial delivery systems. In such approaches, the  conventional 
antibiotics can be loaded into the nanoparticles through physical encapsulation,  adsorption, 
or chemical conjugation. By this way, the pharmacokinetics and therapeutic index of the drug 
can ideally be improved compared to the free form of the drug. The aimed-for advantages are 
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provided by the improved serum solubility, prolonged systemic circulation lifetime of the 
drug, targeted delivery of the drug to the site of infection, sustained and controlled release 
of the drug, and also combinatorial drug delivery to the site of interest that could be reached 
by virtue of the nanoscopic delivery system [26–28]. This rationale of nanotherapeutics in 
this case aimed to enhance the therapeutic effect and minimize the side effects of antibiotics, 
starts with the appropriate design of nanoparticles. In nanoparticles design, the particle size, 
surface properties, and the release profile of the therapeutic agent have vital impact on the 
success of the therapeutic approach. Various nanoparticles-based drug delivery systems have 
been designed and investigated for improving the efficacy of antibiotics of the administered 
drugs, the most common of which shall be outlined in the following.
Lipid-based nanoparticles are widely used for the delivery of antibacterial agents. They can 
be designed as liposomes, solid lipid nanoparticles (SLN), and nanostructured lipid  carriers 
(NLC). Liposomes are one of the most studied nanosystems for antimicrobial therapy in 
various diseases. Liposomes are spherical lipid vesicles with bilayered membrane struc-
ture, consisting of amphiphilic lipid molecules. Since their structure is similar to the bacte-
rial cell membrane, efficacious interaction between liposomes and cells can be obtained. 
These interactions may create adsorption, endocytosis, lipid exchange, and fusion of the 
liposomes. Especially, the design of liposomes that cause fusion and is known as fusogenic 
is the most attractive one in the sense of efficiency. Fusogenic liposomes are able to desta-
bilize the bacterial membrane and release their therapeutic content inside the cells [29, 30]. 
The structure of liposomes, where an aqueous cavity is surrounded by lipid membranes, 
empowers them to transport both lipophilic and hydrophilic drugs (in lipid bilayers and 
aqueous compartments, respectively) without chemical modification, protecting them from 
degradation [31]. SLNs are composed of a solid lipid core stabilized by surfactants and are 
moderately amorphous structures in which bilayers are not distinguished. They can provide 
long-term stability and better incorporation efficacy for hydrophobic drugs and can be eas-
ily scaled-up in production. NLCs were developed in order to overcome the limitations of 
SLNs regarding low-loading capacity for nonhydrophobic drugs and their stability issues. 
In the NLC structure, liquid lipids are used to stabilize the construct, which allows a bipha-
sic drug release profile with initial burst release continued with sustained drug release. 
Liposomes have shown to be successful in combating resistant pathogens. Especially, their 
modified designs are used to improve the potency of formulations in bacterial resistance 
and clearance [32]. Additionally, researchers have confirmed the feasibility of SLN and NCL 
as drug carriers, however, their advantages over liposomes have not been confirmed with 
human data [33]. Most of the research on SLN and NCL as antimicrobial carriers are still in 
the preclinical stage.
To date, a significant number of reports on the activity of antibiotic-conjugated polymeric 
nanoparticles against various infections, including those caused by drug-resistant pathogens, 
have been published [34]. Notably, high biocompatibility of these structures, additional to 
improved pharmacokinetic properties, supports the potential of these nanosystems as new 
tools to treat infections. Polymeric nanoparticles can be prepared from natural and synthetic 
polymers with the prerequisite of biocompatibility and biodegradability. In the polymeric 
antibacterial drug delivery systems, drug molecules can be incorporated in the internal 
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part of the particles, on the surface of polymeric nanocarriers with covalent or non-covalent 
bonds, imprinted in the polymeric nanoparticles or encapsulated in the stimuli-responsive 
shell of polymeric nanoparticles [34]. The encapsulation route of the drug into the polymeric 
nanoparticle drug delivery system plays a key role in the nanocarriers’ pharmacokinetic pro-
file. The action mechanism of the polymeric nanoparticles is defined by the physicochemical 
properties and the composition of the particles. Polymeric nanoparticles may interact with 
the bacterial cell wall via passive or active targeting. Passive targeting is based on particle 
size and the ability of particles to disturb the structure of bacterial membrane leading to pore 
formation in the membrane. For active targeting of polymeric nanoparticles, the surface of 
polymeric nanoparticles is usually functionalized with specific antibodies and aptamer bac-
teriophage proteins providing specific identification for the detection of pathogens and inter-
action between the particles and pathogens. The reported studies reveal that both the active 
and passive targeting strategies to deliver antimicrobial agents with polymeric nanoparticles 
improve their activities compared to their free forms [35–37].
Dendrimers are highly branched macromolecules employed as antibacterial drug delivery 
systems. The unique properties of dendrimers, such as well-defined 3D structures, available 
functional groups, and their ability to mimic cell membranes, make them potential drug car-
riers. Both hydrophobic and hydrophilic drug molecules can be incorporated separately or 
at the same time into dendrimer structures. Lipophilic molecules can be incorporated inside 
the cavity of dendrimers, and hydrophilic agents can be covalently or physically attached to 
the surfaces of dendrimers. The antibacterial can be used in the building of dendrimer blocks, 
whereby the synthesized dendrimers themselves become potent antimicrobials. Dendrimers 
aid to improve the solubility, penetration, and controlled release of the drug molecules. 
Currently, the existing research in the design of dendrimers as antibacterial drug delivery 
systems also focuses on species-selective dendrimer biocide formulations. For instance, pep-
tide, glycol, and glycopeptide dendrimer designs provide effective therapy for the bacterial 
infections.
An inorganic nanomaterial, in contrast to the organic materials listed above, which has also 
shown promise for antibacterial therapies is mesoporous silica nanoparticles (MSNs). In the 
design of MSN-based drug delivery systems, their advantageous characteristics (biocom-
patibility, high surface area, tunable particle diameter, mesoporous structure, and ease of 
functionalization) have been exploited. The designs with targeted and sustained release mech-
anisms make them powerful candidates also for antibacterial therapies. In the use of MSNs as 
drug delivery vehicles for antibacterial therapeutics, their surface functionality along with the 
size and shape are crucial parameters to improve and optimize the efficacy [38]. Their surface 
functionalities can be modified to target both planktonic bacteria and biofilms [39]. In recent 
studies, the utility of MSN for efficient antibiotic delivery [36, 40, 41] and hybrid antibacterial 
materials preparation by incorporating antibacterial enzymes [42], peptides [43], metal ions/
particles [44], and polymers (surface modifiers) [45] to MSNs has been reported.
For rational and efficient utilization of these nanomaterial-based drug delivery systems, 
 systematic investigation of pharmacokinetics and biodistribution should be carried out. The 
pharmacokinetics and biodistribution of nanoparticles are defined by their  physicochemical 
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properties [38]. Apart from their physicochemical properties, the administration routes 
and their elimination from the body need to be systematically evaluated. Hence, thorough 
 evaluation of the current nanoparticle-based drug delivery systems in antibacterial  therapies 
is important for their translation into the clinic. To date, four liposomal/lipid complex drug 
delivery systems for antibiotic delivery have been approved for use in human patients, includ-
ing Abelcet, AmBisome, Amphotec, and Fungisome [46]. This should come as no  surprise 
with regard that a liposomal formulation was the first nanodrug to hit the market in 1995 
(Doxil®), and they have been studied since the early 1980s.
2.2. Nanomaterials as active antibacterial agents
Various types of inorganic and organic nanoparticles have been utilized as antibacterial agents. 
The inherent antibacterial properties of some metals and metal oxides have been known for cen-
turies. An important advantage of antibacterial metal and metal oxide nanoparticles is that they 
have multiple modes of action, which is why microbes can scarcely develop resistance to them.
Among the inorganic antibacterial particles, silver nanoparticles are the most intensively 
investigated ones and capable to kill both Gram-positive and Gram-negative bacteria, having 
even shown to be effective against drug-resistant species [46]. Besides silver nanoparticles, 
other metal nanomaterials have also been studied for antimicrobial treatment, including 
gold [47], copper [48, 49], tellurium [50, 51], and bismuth [52]. Moreover, many studies have 
revealed the antibacterial activity of metal oxide nanomaterials, such as zinc oxide (ZnO) [53], 
copper oxide (CuO) [54, 55], magnesium oxide (MgO), nitric oxide (NO) [56], titanium  dioxide 
(TiO
2
) [57], aluminum oxide (Al
2
O
3
) [58], magnetic iron oxide (α-Fe
2
O
3
) [59], and cerium oxide 
(CeO
2
) [60] nanoparticles. The toxic mode of metal and metal oxide  nanoparticles against 
bacterial cells has been associated with ROS generation and membrane  disruption [61]. 
According to literature findings, the release of ions is designated as the driving force behind 
the antimicrobial properties of antibacterial nanoparticles.
Cationic polymeric nanoparticles have been considered as promising organic antibacterial 
nanoparticles. They can be composed of natural or synthetic cationic polymers. The antibacte-
rial polymeric nanoparticles kill microorganisms upon their contact with bacterial cells due to 
the strong interaction of their cationic surfaces with the bacterial cells [62]. The mechanisms 
of action have been proposed for how these cationic groups are able to disrupt the bacterial 
cell membrane, with some requiring hydrophobic chains of certain lengths to penetrate and 
burst the bacterial membrane. Moreover, different polymeric nanosized antibacterials with 
long-term antibacterial activity, chemically stable, and ability to bind to surfaces of interest 
have been reported. These include lipid nanoparticles, quaternary ammonium polyethylenei-
mine-incorporated polymeric nanoparticles [63, 64], chitosan [65], and self- assembled peptide 
nanoparticles [66]. In addition to the above-mentioned metallic and polymeric nanoparticles, 
carbon-based nanostructures have shown antibacterial effects. For instance, the antibacte-
rial activity of fullerene [67] and carbon nanotubes [68, 69] ( single-walled or multi-walled) 
derivatives have been observed. However, the antibacterial mechanism of carbon-based nano-
structures is still under debate and has not received particular attention, possibly due to the 
difficulties of their dispersion in water, especially in case of the carbon nanotubes [70].
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3. Advantages and challenges of nanotechnology-based antibacterial 
treatments
Promising approaches for the effective delivery of therapeutic compounds can be provided 
by the use of nanoparticles as drug carriers. Literature findings and clinical results have 
surely presented several clinical advantages of antimicrobial nanoparticles and their utiliza-
tion as drug carrier systems. Antimicrobial nanoparticles are of great interest as they provide 
a number of benefits over free antimicrobial agents. In detail, nanocarriers can conquer the 
solubility and stability issues and reduce side effects [62]. With the use of nanocarriers in the 
delivery of drugs, combination drug therapy can be achieved by incorporating two or more 
drugs or different therapeutic modalities into the carrier matrix. The surface modifications 
can be carried out by conjugating targeting ligands on the nanocarriers that are not known 
by the immune system and specifically targeted to special microorganisms. Administration 
of  antimicrobial agents using nanoparticles can increase the overall pharmacokinetics by 
progressing therapeutic index, extending drug circulation, and providing controlled drug 
release. Multiple mechanisms of action can be provided by the antibacterial nanoparticles, 
which prevent the development of antibacterial resistance by many pathogenic bacteria. 
Several routes of administration, including oral, nasal, parenteral, intraocular, and so on, can 
be employed with the nanotechnology-based antibacterial treatments.
The significant advantages of nanomaterials as antimicrobial agents are their modularity 
in design, enabling a multimodal approach that makes it especially difficult for bacteria to 
develop resistance mechanisms against these. Namely, a nanotechnology-based antibacterial 
agent can be constructed out of several components that possess antimicrobial activities in 
themselves, such as, for instant, be composed of an antibacterial core material (e.g. metal or 
metal oxide) surrounded with an antibacterial polymeric shell or coating, in which  antibiotic 
drugs could be incorporated [71]. The core material could further be “prickly,” which physi-
cally can destroy the bacterial cell wall by a “nano-piercing” process once the polymeric shell 
has been dissolved, leading to the disruption of bacterial integrity and lysis, as presented 
in a recent study by Wu et al. where zinc-doped copper oxide prickly nanoparticles exhib-
ited high bacterial killing efficiency owing to the provided core particle nanostructure [72]. 
Furthermore, varying possibilities for combination therapy together with existing (commer-
cial) antibiotics to reach synergistic effects are evident [14, 73, 74].
Although nanoparticle-based antibacterial treatments promise significant benefits and 
advances in addressing the key hurdles in treating infectious diseases, there are challenges in 
translating this exciting technology for clinical use. These include thoroughly evaluating the 
interactions of nanoparticles with cells, tissues, and organs, which accordingly recalibrates 
doses and identifies proper administration routes to obtain desired therapeutic effects. Hence, 
to provide a clinical translation of nanomaterials, standardized in vitro experimentations that 
will provide in vivo relevant data should be established [75]. In section 4, we describe existing 
in vitro methods for testing antimicrobial activity. In addition, the current methods commonly 
employed in testing the antibacterial and anti-biofilm activity of nanoparticles are discussed 
with the relevancy and pitfalls.
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4. Methods to study antimicrobial activity in vitro
Traditionally, antimicrobial research has focused on planktonic bacteria, and there is a 
 variety of test methods available for evaluation of antimicrobial activity against planktonic 
cells [76]. The Clinical and Laboratory Standards Institute (CLSI) and European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) are the major contributors to harmo-
nized antimicrobial susceptibility testing (AST) providing uniform procedures for testing 
and  analysis of antibacterial activity. CLSI standards clearly define the specific and essen-
tial requirements for materials, methods, and methodologies that need to be followed 
without any  modifications because deviations from the approved procedures might affect 
the experimental outcome [77]. All the critical elements for the testing, such as the culture 
medium, inoculum density, and incubation conditions, are listed. Unlike the antibacterial 
assays, standardized methods for anti-biofilm studies are scarce. No standard methods have 
been approved by CLSI or EUCAST for evaluation of antimicrobial activity against biofilms. 
Altogether, five standards (ASTM E2196, ASTM E2647, ASTM E2562, ASTM E2799, and ASTM 
E2871) set by the American Society for Testing and Materials (ASTM) exist, and they all are 
 applicable as such only for Pseudomonas aeruginosa biofilms [78]. Moreover, only one standard 
is intended for susceptibility testing. Further, due to distinct phenotype and heterogeneity of 
biofilm  bacteria, conventional in vitro methods used for assessment of bacterial susceptibility 
to antimicrobials are not appropriate for biofilm-growing bacteria [79]. Lack of standardiza-
tion makes a comparison of the test results difficult, and further, can lead to the generation of 
conflicting data between studies since the experimental outcome is strongly dependent on the 
assay conditions and materials employed in the testing.
4.1. Antimicrobial susceptibility testing
In vitro susceptibility assays are performed to assess the antimicrobial susceptibility of microor-
ganisms in order to provide efficient treatment for infections [80]. Moreover, they are used for 
resistance surveillance and in research laboratories to study antimicrobial activity of antimicrobial 
agents. Determination of the minimum inhibitory concentration (MIC) is the most widely used 
measure of the antimicrobial susceptibility of microorganisms. The MIC is defined as the lowest 
concentration of an antimicrobial (expressed as mg/L or μg/μL) required to inhibit the visible 
growth after overnight incubation. In addition, the minimum bactericidal concentration (MBC) is 
frequently used. The MBC refers to the lowest concentration of an antimicrobial that kills 99.9% 
of the original inoculum after a certain incubation period (Figure 1). These measures can be eas-
ily achieved and compared with each other when standardized methodologies and protocols are 
followed. A number of guidelines and standardized protocols for MIC and MBC determinations 
exist that include information on each step of the testing, ranging from storage and preparation of 
antibiotic stocks to interpretation of the results against particular microorganisms [81].
4.1.1. Dilution methods
Dilution methods are used to determine the MIC values of the antimicrobial agents. Moreover, 
they serve as reference methods for antimicrobial susceptibility testing. The minimum  inhibitory 
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concentration can be determined both on agar (agar dilution) and in broth (broth dilution). 
Standards for agar and broth dilution techniques used to assess the in vitro susceptibility of 
aerobically grown bacteria are described in CLSI document M07-A9. The document covers 
the performance, experimental conditions, reporting of the minimal inhibitory concentration 
(MIC), quality control procedures, and limitations of the recommended methods.
When conducted on agar, a two-fold diluted series of the antimicrobial agent is incorporated 
into agar medium followed by inoculation of standardized suspension of the given  organism 
onto the agar plate. Broth dilution can be performed in tubes (macrodilution, volume 2 ml) 
or in microtiter well plates (microdilution, volume ≤500 μl) containing a two-fold diluted 
series of antimicrobial agent prepared in the liquid growth medium that is inoculated with 
a standard inoculum of bacteria followed by a defined incubation period under particular 
conditions. After the incubation, the outcome is read based on turbidity or growth zones, 
and the MIC is defined. The MIC value can also be utilized to distinguish between bacteri-
cidal and  bacteriostatic activities. Alternatively, when using microdilution, the MIC can be 
 determined spectrophotometrically according to the EUCAST protocol [81]. In addition to 
CLSI and EUCAST standards, ISO-20776-1 standard proposes acceptable performance criteria 
for microdilution method. After broth dilutions, the MBC can be determined by  sub- culturing 
the samples from tubes or wells and plating on agar to determine the number of cells (CFU/
ml) after incubation for 24 h. Then, MBC is defined as the lowest concentration at which 99.9% 
of the final inoculum is killed (Figure 1). The main advantage of the dilution method is a gen-
Figure 1. Minimum inhibitory concentration (MIC) versus minimum bactericidal concentration (MBC).
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eration of quantitative data, the MIC value. Moreover, the assay is overall reproducible, and 
small amounts of antimicrobials are needed when the microdilution method is utilized. By 
contrast, large amounts of antimicrobial agents are needed in macrodilution testing. The main 
disadvantage of the method is several steps in sample preparation, which in turn, increases 
the possibility of errors.
4.1.2. Diffusion methods
Standards for antimicrobial disk susceptibility test are proposed in the document M02-A12 by 
the CLSI. Specifications for the agar (type, depth), concentration range of the test antimicro-
bial, concentration of the microorganism and incubation conditions (time, temperature and 
atmosphere) are included. Also, interpretation of the results, quality control procedures, and 
limitations of the methods when used for susceptibility testing of aerobically growing bacte-
ria are described. Agar disk diffusion method is routinely applied to the in vitro susceptibil-
ity testing of bacteria. The Kirby-Bauer test is the most thoroughly described disk diffusion 
method for which interpretive standards exist (Figure 2). A filter paper disc impregnated with 
antimicrobials at different concentrations is placed on an agar plate, and the antimicrobial 
diffuses from the disc into the agar around the disc. Thereafter, the plate is inoculated with 
a standardized suspension of a microorganism followed by incubation. After the incubation 
period, the growth inhibition zones around the discs are measured. The diameter of the zone 
is depending on the antimicrobial susceptibility of microorganism. The disc diffusion test is 
simple to perform, but it only provides qualitative data and categorizes microorganisms as 
susceptible, intermediate, and resistant based on the susceptibility. Thus, it cannot be used 
to distinguish between bactericidal and bacteriostatic effects. Commercially available zone 
reader systems can be utilized to calculate an approximate MIC value by comparing the zone 
size and standard curve of the bacteria and antibiotic stored in an algorithm [82].
4.1.3. Combined dilution and diffusion method
The antimicrobial gradient diffusion method is based on the establishment of an antimicro-
bial concentration gradient in the agar medium to measure the antimicrobial susceptibility. 
Thin plastic test strips marked with concentration scale and impregnated with antibiotic 
 concentration gradient are placed on agar plates that have been inoculated with a  standardized 
Figure 2. Disk diffusion test and antimicrobial gradient diffusion method. On the left, agar plate showing zone of 
inhibition by different antimicrobials of diameter of zones of inhibition refers to the susceptibility of a microorganism.
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inoculum (Figure 2). After incubation overnight, the experimental outcome is read, and the 
MIC can be determined by the intersection of the lowest part of the ellipse-shaped growth 
inhibition area with the test strip. E-Test is the commercially available test for this purpose.
4.1.4. Time-kill test
Time-kill assay is complementary to MIC and MBC determinations. It provides information 
on the dynamic interaction between the antimicrobial and microorganism, thus revealing 
whether the antimicrobial effect is time or concentration dependent. Such activities can be 
investigated utilizing the standard protocol M26-A by CLSI and ASTM2315. These protocols 
are frequently modified. Time-kill assay is usually conducted at a concentration twice or four 
times the MIC. Standardized inoculum is added to a nutrient broth containing the antimicro-
bial at various concentrations. A sample is taken from each concentration at the inoculation 
time and after selected time points. Samples are serially diluted and viable plate counts are 
performed. The kill curves are constructed by plotting the log CFU against time. A 3-log reduc-
tion in cell counts corresponding the killing of 99.9% is considered as significant antimicro-
bial activity [83]. Alternatively, measurement of luminescence can be utilized to determine the 
time-kill relationship. Luminescence is detected by the ATP assay, in which adenosine triphos-
phate (ATP), an indicator for bacterial viability is quantified, and the number of viable cells is 
determined based on the amount of ATP. The assay uses luciferase reaction, in which luciferin 
is converted to oxyluciferin in the presence of molecular oxygen and ATP, and generates light 
by luminescence. Luminescent signal is proportional to the number of viable cells [84].
4.1.5. Methods to study antimicrobial susceptibility of biofilms
Since conventional susceptibility testing methods are not applicable for biofilms, and the 
MIC values do not provide a valid estimation of the antibiotic concentration needed to treat 
biofilm-related infections, the minimum biofilm inhibitory concentration (MBIC) has been 
determined instead. The MBIC determines the susceptibility of bacteria when the biofilm is 
forming and refers to the lowest concentration of an antimicrobial, in which no visible growth 
occurs after exposure to antimicrobial after the incubation period, and it can be recorded by 
optical reading [85]. Based upon the viable plate counts, the MBIC is defined as the lowest 
antimicrobial concentration in which there is no time-dependent increase in the mean number 
of viable cells between two exposure times [86]. Moreover, the Calgary Biofilm Device (CBD) 
can be used for determination of MBIC, as well as the minimum biofilm eradication concen-
tration (MBEC), which is defined as the lowest concentration of an antimicrobial required to 
eradicate the established biofilms [87] along with susceptibility of planktonic bacteria (MIC) 
[22]. The commercially available CBD consists of 96 pegs mounted on the lid of a 96-microtiter 
well plate. Biofilms are first formed on the pegs for a defined time period. After the incubation 
period, the lid is transferred to another 96-well plate containing antimicrobials in fresh culture 
media at various concentrations. The MBEC is defined as the concentration of antimicrobial in 
which no visible growth can be detected [88]. ASTM 2799 standard describes the operational 
parameters required to grow, treat, sample, and analyze Pseudomonas aeruginosa biofilms 
using MBEC assay. In this assay, the experimental outcome is reported as log10 colony form-
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ing units (CFUs) per surface area, and the antimicrobial efficacy is assessed as the log10 reduc-
tion of viable cells. The experimental outcome can be evaluated using the CLSI guidelines for 
interpretation. However, breakpoints for resistance are not available, and those for planktonic 
bacteria are not applicable for biofilm bacteria [86]. Even though the ASTM protocol describes 
the specific experimental conditions only for P. aeruginosa biofilms, it can be used for other 
species with some modifications.
4.2. Methods to assess the anti-biofilm activity
Several assays with distinct endpoints are essential for the determination of the antimicrobial 
activity against biofilms. These assays rely on quantification of (i) viable cells in the biofilm, (ii) 
total biomass and (iii) biofilm matrix. An ideal anti-biofilm agent would target biofilm viability, 
biomass, and the matrix. Most of the assays are based on various staining methods. Several 
models have been proposed for evaluation of antimicrobial activity on biofilms. Depending on 
the flow of nutrients and bypass the waste products, biofilm models can be classified as closed 
and open systems [89]. Microtiter well plate-based assays are the most commonly used, while 
the Calgary biofilm device, substratum suspending reactors, and the flow cell system are the 
most widely used biofilm models for in vitro susceptibility testing [79]. Because the experi-
mental outcome is affected by the choice of the model system, it is utmost important to select a 
model, in which biofilms can be formed in conditions close to in vivo settings.
4.2.1. Crystal violet staining
Crystal violet (Hexamethyl pararosaniline chloride, CV) assay is not only one of the oldest 
but also most widely used staining methods applied to biofilm quantification [90, 91]. Crystal 
violet is an inexpensive and basic dye that is used to measure the effects on total biomass of 
biofilms. Crystal violet binds indifferently to both negatively charged bacteria and polysac-
charides present in the EPS. After staining, adsorbed dye is eluted in a solvent, such as acetic 
acid or ethanol. The amount of the dye solubilized by the solvent is measured spectrophoto-
metrically, and it is directly proportional to biofilm biomass [92, 93]. Disadvantages of the 
method are shortcomings in its dynamic range, laboriousness, and low reproducibility [92]. 
Experimental conditions, bacterial species, concentration, and nature of the solvent used, as 
well as incubation time are crucial steps that affect the experimental outcome. Furthermore, 
the assay does not sort out living or dead cells or biofilm matrix, thus not providing any infor-
mation on the number of living bacterial cells [93] and, more importantly, imprecise informa-
tion on the antimicrobial activity. However, the method can be used for both Gram-negative 
and Gram-positive bacteria and fungi, but the optimal assay conditions, such as temperature, 
incubation time, and solvent, vary between species [94, 95].
4.2.2. Resazurin staining
Resazurin, also known as alamar blue (7-hydroxy-3H-phenoxazin-3-one-10-oxide), is a non-
invasive, non-fluorescent dye, which is reduced to resorufin, a pink, fluorescent dye as a result of 
metabolically active cells and bacterial viability. Resorufin is detected  spectrophotometrically 
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to determine the viable cells [96]. Resazurin staining assay can be used to assess the antimi-
crobial activity based on the effects on viability of various microorganisms grown in suspen-
sions or as biofilms [97]. However, time of resazurin reduction is species and strain specific. 
Consequently, the experimental conditions, such as incubation time and resazurin concentra-
tion, need to be optimized to obtain reproducible data [93, 98].
4.2.3. Fluorescein diacetate (FDA) assay
The assay is used to measure nonspecific esterase activity of viable microbial cells that con-
verts colorless, nonfluorescent FDA to fluorescein, which is a green fluorescent compound 
that can be quantified fluorometrically [88]. The assay is not widely used because the dye 
rapidly leaks from the cells and is unstable. Moreover, hydrolysis of FDA to fluorescein in the 
absence of live cells and quenching of fluorescence by assay solutions may also occur under 
certain conditions, thus making the reliability of the assay questionable. However, the assay 
enables biofilm quantification without removing biofilm from the place where it has been 
formed, allowing the quantification of entire biofilm [84, 99].
4.2.4. Other viability assays
Biofilm viability can be assessed using tetrazolium salt reduction assay, in which  tetrazolium 
salts, such as MTT (3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), XTT 
(2,3-bis-[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide), and MTS (3-[4, 
5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium), are 
reduced to formazan dyes. The color change can be quantified spectrophotometrically. The 
amount of formazan dye produced is proportional to the number of viable cells. However, 
the amount of reductase enzyme produced by cells is dependent on metabolic activity [100, 
101]. In other words, cells that are metabolically less active when encased in a biofilm produce 
also reduced amount of reductase enzyme that can lead to identification of artificially low 
quantities of cells when viable cells are detected using this assay. Moreover, high densities of 
bacteria may produce the maximum amount of formazan product leading to optical densities 
comparable with even higher cell densities [102].
4.2.5. Viable plate counts (colony forming units)
Viable plate counts (colony forming unit counting) are used to assess the biofilm viability 
based on cell counting. The assay can be used to evaluate the efficacy of antimicrobials to 
prevent biofilm formation or eradicate pre-formed biofilms, respectively [103]. Depending on 
the assay mode, bacteria and antimicrobials are added simultaneously to the microtiter well 
plates or biofilms are first allowed to form followed by the exposure to antimicrobial. After 
an incubation period, biofilms are dislodged and disaggregated. The resulting suspensions 
are carefully homogenized, for example, by vortexing or sonication [93]. Subsequently, sus-
pensions are serially diluted and plated or spread on agar. Colony forming units (CFUs) per 
surface area or volume are counted after an incubation period. The experimental outcome can 
be evaluated as reduction in CFUs compared to untreated control biofilms. The method gives 
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accurate information on bacterial viability [94]. However, it is regarded as a time- consuming 
and laborious methodology because of serial dilutions and plating. Additionally, special 
attention needs to be addressed to the detachment and disaggregation steps to avoid false 
negative/positive results. The complete recovery and disaggregation of biofilm need to be 
ensured by applying methods that do not affect viability of the biofilm cells [93, 104].
4.3. Testing of antimicrobial activities of nanoparticles
With respect to the evaluation of antimicrobial activity of nanoparticles, only one specific stan-
dard is set by the International Organization for Standardization (ISO), and it is intended for 
determination of the antimicrobial potency of silver nanoparticles against Staphylococcus aureus 
by measuring the release of muramic acid using gas  chromatography-mass spectrometry 
(GC-MS) [105]. Thus, conventional methodologies for antimicrobial susceptibility testing 
have been not only adapted but also modified for investigation of antimicrobial activity of 
various nanoparticles [102]. In antimicrobial testing, experimental outcome is affected by 
many factors, such as solvent, inoculum preparation, type of the culture media, and incu-
bation conditions, and these factors have been also found to be influential when testing 
 antimicrobial activities of nanoparticles [76, 106]. For example, choice of the culture media 
can have a substantial impact on antimicrobial activity of nanoparticles. Media composition 
and its pH may affect the experimental outcome because of the impact on physicochemical 
properties of nanoparticles, and further, media type (solid vs. liquid) has found to profoundly 
influence the antimicrobial activity of nanoparticles [1, 107, 108].
Both standardized and modified microdilution and macrodilution methods have been applied 
to the determination of MIC and MBC values to evaluate the antimicrobial susceptibility of se-
veral microorganisms to nanoparticles [76, 109, 110–116]. Additionally, resazurin staining assay 
has been employed to determine the MIC. The MIC was recorded as the lowest concentration 
at which color change from blue to pink occurred [117]. Even though standardized antimicro-
bial susceptibility testing protocols can be followed, no standards describing the synthesis of 
nanoparticles exist. Differences in the synthesis methodology are known to impact the particle 
size and chemical composition of the nanoparticles, which, in turn, can further affect the anti-
microbial activity and cause variability in the experimental outcome [1, 118]. Hence, the impact 
of such factors has to be taken into consideration when results between studies are compared.
Diffusion methods can be applied alongside dilution assays to confirm the antimicrobial 
susceptibility of microorganisms [108, 119, 120]. Agar disk diffusion tests performed both 
according to the standardized protocols and with modifications are frequently used for sus-
ceptibility assessment and evaluation of antimicrobial activity of nanoparticles [109, 121–124]. 
Paper disc method has been employed as an alternative to standardized single disk method 
[112]. Further, agar well diffusion assays have been successfully utilized for the evaluation of 
antimicrobial effects of nanoparticles [120, 125, 126].
Antimicrobial effects can also be determined by reading the optical density [125]. Even though 
measurement of optical density is a straightforward method, it is not the most suitable for 
measuring the activity of nanoparticles because nanoparticles as such can also interfere with 
the optical density [46, 127]. Viable plate counts have been frequently performed according to 
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the various protocols to assess the antimicrobial efficacy of nanoparticles against both plank-
tonic and biofilm-growing bacteria [109, 128, 110–112, 116]. Samples can either be spread or 
pipetted on agar plates followed by overnight incubation and determination of the number 
of CFUs [116, 111, 113–115]. Especially, when quantifying the biofilm bacteria, efficient disag-
gregation of samples is of great importance to avoid false positive results.
Crystal violet staining is the most widely applied staining assay to investigate the  antimicrobial 
activity of the various nanoparticles against biofilm-growing bacteria [129, 130, 121, 116, 131, 
132]. By combining assays that quantify different features of biofilms, more relevant informa-
tion on the activity of nanoparticles can be obtained. In that context, effects of nanoparticles 
on  biofilm inhibition have been studied using viable plate counts and crystal violet staining in 
parallel [133, 134]. Additionally, LIVE/DEAD and crystal violet staining has been combined for 
the same purpose [133, 134]. Crystal violet staining has been also used together with resazurin 
staining assay to assess the impact of nanoparticles on total biomass, including the matrix com-
ponents and biofilm viability, respectively [135]. Further, crystal violet along with  phenol has 
been applied to quantify the effects on biomass and EPS [136]. Antimicrobial agents  displaying 
bactericidal effects have usually an impact on both viability and biomass, while antimicrobials 
acting like detergents affect only the biomass [137]. Further, to distinguish between bactericidal 
and bacteriostatic activities, LIVE and DEAD staining of bacterial biofilms can be conducted 
using a combination of fluorescein diacetate (FDA) and propidium iodide (PI) dyes or by com-
mercially available LIVE/DEAD kit containing propidium iodide (PI) and SYTO9 fluorescent 
dyes [136, 138]. Commonly used microtiter well plate-based assays are summarized in Table 1.
In order to gain information on the mechanistic action of nanoparticles, antimicrobial assays 
can be conducted in two modes, prior to and post biofilm formation. In the pre-exposure 
mode, nanoparticles and bacteria are simultaneously added, whereas in post-exposure mode, 
biofilms are first allowed to form, followed by the exposure to nanoparticles. Crystal vio-
let staining has been used to evaluate the impact of nanoparticles on biofilm formation and 
eradication, respectively [139, 140, 127, 141], and viable plate counts have been utilized in the 
Assays Endpoint Read-out Planktonic 
bacteria
Biofilm Ref.
Measurement of optical 
density
Growth 
inhibition, MIC
Absorbance X X [119, 125]
Resazurin staining assay Viability, MIC Fluorescence X X [117, 136]
Tetrazolium salt 
reduction assay (MTT, 
XTT, MTS)
Viability Fluorescence X X [111, 132, 142, 143]
Crystal violet staining 
assay
Biofilm biomass, 
MBIC
Absorbance – X [132]
Fluorescein diacetate 
(FDA) assay
Viability Fluorescence X X [143, 144]
Table 1. Microtiter well plate–based assays used to investigate antimicrobial activity of various nanoparticles.
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 investigation of the antimicrobial efficacy of nanoparticles in the prevention of biofilm forma-
tion and eradication of pre-formed biofilms [111, 112].
5. Conclusion
There is a strong demand to develop novel antimicrobial materials, and the emergence of 
nano-technology is creating a variety of options in this respect. Numerous nanoparticles 
exhibit antibacterial activity against several bacterial species. Today, nanomaterials are a 
promising platform to control bacterial infections in a broad range of applications. However, 
the absence of standardizations in testing methods leads to inconsistency in results. The fore-
most requirement of the assays applied to the evaluation of antimicrobial activity is repro-
ducibility. Antimicrobial activity should be tested against various microorganisms, preferably 
against representatives of both Gram-negative and Gram-positive species. Moreover, a com-
bination of several assays is preferred to confirm the activity. Several standardized method-
ologies exist for testing the antibacterial activity of conventional agents against planktonic 
bacteria. These methods are not applicable for biofilms, and further, they do not allow the 
prediction of the in vivo activity against biofilm-growing bacteria. The majority of the bacte-
rial infections are nowadays attributed to biofilm formation, standardized test methods are 
urgently needed for more accurate evaluation of antimicrobial activity against biofilms. Even 
though nanoparticles represent a prominent approach to combat both multi-drug resistant 
and biofilm-related infections, lack of standardization of synthesis and testing methodologies 
is a significant concern. Several assays have been reported so far to test the anti-biofilm activity 
of nanoparticles-containing formulations. However, since antimicrobial assays are sensitive 
to variation in assay conditions, only standardization of these methods enables comparative 
analysis between studies.
Author details
Didem Şen Karaman1*, Suvi Manner1, Adyary Fallarero2 and Jessica M. Rosenholm1
*Address all correspondence to: dsen@abo.fi
1 Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi 
University, Turku, Finland
2 Pharmaceutical Biology, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, 
University of Helsinki, Finland
References
[1] Rizzello L, Pompa PP. Nanosilver-based antibacterial drugs and devices: Mechanisms, 
methodological drawbacks, and guidelines. Chem Soc Rev. 2014;43(5):1501–18.
Antibacterial Agents76
[2] Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phe-
nomenon. Pathog Glob Health. 2015;109(7):309–18.
[3] Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment 
of incentive strategies for discovery and development of novel antibiotics. J Antibiot 
(Tokyo). 2016;69(2):73–88.
[4] Tor Y, Fair R. Antibiotics and bacterial resistance in the 21st century. Perspect Med 
Chem. 2014;6:25–64.
[5] Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug 
Discov. 2003;2(2):114–22.
[6] Worthington RJ, Richards JJ, Melander C. Small molecule control of bacterial biofilms. 
Org Biomol Chem. 2012;10(37):7457.
[7] Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS. 2013;121:1–58.
[8] Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, 
consequences, and management. Front Public Health. 2014;2(145) 1–8.
[9] Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 
2015;40(4):277–83.
[10] Luyt C-E, Bréchot N, Trouillet J-L, Chastre J. Antibiotic stewardship in the intensive care 
unit. Crit Care. 2014;18(480)1–12.
[11] Katz ML, Mueller LV, Polyakov M, Weinstock SF. Where have all the antibiotic patents 
gone? Nat Biotechnol. 2006;24(12):1529–31.
[12] Penesyan A, Gillings M, Paulsen I. Antibiotic discovery: combatting bacterial resistance 
in cells and in biofilm communities. Molecules. 2015;20(4):5286–98.
[13] Levy SB. Factors impacting on the problem of antibiotic resistance. J Antimicrob 
Chemother. 2002;49(1):25–30.
[14] Rogers SA, Huigens RW, Cavanagh J, Melander C. Synergistic effects between conven-
tional antibiotics and 2-aminoimidazole-derived antibiofilm agents. Antimicrob Agents 
Chemother. 2010;54(5):2112–8.
[15] Cheng G, Dai M, Ahmed S, Hao H, Wang X, Yuan Z. antimicrobial drugs in fighting 
against antimicrobial resistance. Front Microbiol. 2016;7(470):1–11.
[16] Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant 
 microorganisms. Clin Microbiol Rev. 2002;15(2):167–93.
[17] Stewart PS, William Costerton J. Antibiotic resistance of bacteria in biofilms. Lancet. 
2001;358(9276):135–8.
[18] Bordi C, de Bentzmann S. Hacking into bacterial biofilms: a new therapeutic challenge. 
Ann Intensive Care. 2011;1(1):19.
[19] Stewart PS, Franklin MJ. Physiological heterogeneity in biofilms. Nat Rev Microbiol. 
2008;6(3):199–210.
Current Approaches for Exploration of Nanoparticles as Antibacterial Agents
http://dx.doi.org/10.5772/68138
77
[20] Landini P, Antoniani D, Burgess JG, Nijland R. Molecular mechanisms of compounds 
affecting bacterial biofilm formation and dispersal. Appl Microbiol Biotechnol. 2010; 
86(3):813–23.
[21] Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol. 
2002;292(2):107–13.
[22] Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: 
new technology for rapid determination of antibiotic susceptibilities of bacterial  biofilms. 
J Clin Microbiol. 1999;37(6):1771–6.
[23] Piddock LJ. The crisis of no new antibiotics—what is the way forward? Lancet Infect Dis. 
2012;12(3):249–53.
[24] Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24(1):71–109.
[25] Gao W, Thamphiwatana S, Angsantikul P, Zhang L. Nanoparticle approaches against 
bacterial infections: Nanoparticle against bacterial infections. Wiley Interdiscip Rev 
Nanomed Nanobiotechnol. 2014;6(6):532–47.
[26] Rosenholm JM, Mamaeva V, Sahlgren C, Lindén M. Nanoparticles in targeted cancer ther-
apy: mesoporous silica nanoparticles entering preclinical development stage. Nanomed. 
2012;7(1):111–20.
[27] Davis ME, Chen Z (Georgia), Shin DM. Nanoparticle therapeutics: an emerging treat-
ment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–82.
[28] Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: 
therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–9.
[29] Nicolosi D, Scalia M, Nicolosi VM, Pignatello R. Encapsulation in fusogenic liposomes 
broadens the spectrum of action of vancomycin against Gram-negative bacteria. Int J 
Antimicrob Agents. 2010;35(6):553–8.
[30] Watarai S, Iwase T, Tajima T, Yuba E, Kono K, Sekiya Y. Application of pH-sensitive  fusogenic 
polymer-modified liposomes for development of mucosal vaccines. Vet Immunol Immuno-
pathol. 2014;158(1-2):62–72.
[31] Hallaj-Nezhadi S, Hassan M. Nanoliposome-based antibacterial drug delivery. Drug 
Deliv. 2015;22(5):581–9.
[32] Yang K, Gitter B, Rüger R, Wieland GD, Chen M, Liu X, et al. Antimicrobial peptide-modi-
fied liposomes for bacteria targeted delivery of temoporfin in photodynamic  antimicrobial 
chemotherapy. Photochem Photobiol Sci. 2011;10(10):1593.
[33] Boukherroub R. Functionalized nanomaterials for the management of microbial infec-
tion: a strategy to address microbial drug resistance. Boston, MA: Elsevier; 2017.
[34] Michalak G, Głuszek K, Piktel E, Deptuła P, Puszkarz I, Niemirowicz K, et al. Polymeric 
nanoparticles – a novel solution for delivery of antimicrobial agents. Med Stud. 2016;1:56–62.
Antibacterial Agents78
[35] Scott C, Abdelghany, Quinn, Ingram, Gilmore, Donnelly, et al. Gentamicin-loaded 
nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa 
infection. Int J Nanomedicine. 2012;4053.
[36] Kavruk M, Celikbicak O, Ozalp VC, Borsa BA, Hernandez FJ, Bayramoglu G, et al. 
Antibiotic loaded nanocapsules functionalized with aptamer gates for targeted destruc-
tion of pathogens. Chem Commun. 2015;51(40):8492–5.
[37] Barreras US, Méndez FT, Martínez REM, Valencia CS, Rodríguez PRM, Rodríguez JPL. 
Chitosan nanoparticles enhance the antibacterial activity of chlorhexidine in  collagen mem-
branes used for periapical guided tissue regeneration. Mater Sci Eng C. 2016;58:1182–7.
[38] Gupta A, Landis RF, Rotello VM. Nanoparticle-based antimicrobials: surface  functionality 
is critical. F1000Research. 2016;5:364.
[39] Hetrick EM, Shin JH, Paul HS, Schoenfisch MH. Anti-biofilm efficacy of nitric oxide-
releasing silica nanoparticles. Biomaterials. 2009;30(14):2782–9.
[40] Tamanna T, Bulitta JB, Yu A. Controlling antibiotic release from mesoporous silica nano 
drug carriers via self-assembled polyelectrolyte coating. J Mater Sci Mater Med. 2015;26(2).
[41] Lee B-Y, Li Z, Clemens DL, Dillon BJ, Hwang AA, Zink JI, et al. Redox-triggered release of 
moxifloxacin from mesoporous silica nanoparticles functionalized with disulfide snap-
tops enhances efficacy against pneumonic tularemia in mice. Small. 2016;12(27):3690–702.
[42] Li L, Wang H. Enzyme-coated mesoporous silica nanoparticles as efficient antibacterial 
agents in vivo. Adv Healthc Mater. 2013;2(10):1351–60.
[43] Braun K, Pochert A, Lindén M, Davoudi M, Schmidtchen A, Nordström R, et al. Membrane 
interactions of mesoporous silica nanoparticles as carriers of antimicrobial peptides. J 
Colloid Interface Sci. 2016;475:161–70.
[44] Tian Y, Qi J, Zhang W, Cai Q, Jiang X. Facile, One-pot synthesis, and antibacterial activ-
ity of mesoporous silica nanoparticles decorated with well-dispersed silver nanopar-
ticles. ACS Appl Mater Interfaces. 2014;6(15):12038–45.
[45] Şen Karaman D, Sarwar S, Desai D,  Björk E. M, Odén M, Chakrabarti P,  Rosenholm 
J.M,  Chakraborti S. Shape engineering boosts antibacterial activity of chitosan coated 
mesoporous silica nanoparticle doped with silver: a mechanistic investigation. Journal 
of Materials Chemistry B. 2016, 4, 3292–3304.
[46] Zhu X, Radovic-Moreno AF, Wu J, Langer R, Shi J. Nanomedicine in the management of 
microbial infection – Overview and perspectives. Nano Today. 2014;9(4):478–98.
[47] Cui Y, Zhao Y, Tian Y, Zhang W, Lü X, Jiang X. The molecular mechanism of action of 
bactericidal gold nanoparticles on Escherichia coli. Biomaterials. 2012;33(7):2327–33.
[48] Karlsson HL, Cronholm P, Hedberg Y, Tornberg M, De Battice L, Svedhem S, et al. 
Cell membrane damage and protein interaction induced by copper containing nanopar-
ticles—importance of the metal release process. Toxicology. 2013;313(1):59–69.
Current Approaches for Exploration of Nanoparticles as Antibacterial Agents
http://dx.doi.org/10.5772/68138
79
[49] Chatterjee AK, Chakraborty R, Basu T. Mechanism of antibacterial activity of copper 
nanoparticles. Nanotechnology. 2014;25(13):135101.
[50] Zare B, Faramarzi MA, Sepehrizadeh Z, Shakibaie M, Rezaie S, Shahverdi AR. Biosynthesis 
and recovery of rod-shaped tellurium nanoparticles and their bactericidal activities. 
Mater Res Bull. 2012;47(11):3719–25.
[51] Lin Z-H, Lee C-H, Chang H-Y, Chang H-T. Antibacterial activities of tellurium nanoma-
terials. Chem—Asian J. 2012;7(5):930–934.
[52] Claudio C-R, Chellam S. Bismuth nanoparticles: antimicrobials of broad-spectrum, low 
cost and safety.  In: Seifalian A, de Mel A, Kalaskaer  DM, editors Nanomedicine.  One 
Central Press; 2014. Chapter 17 p. 430–438. 
[53] Ansari MA, Khan HM, Khan AA, Sultan A, Azam A. Characterization of clinical strains 
of MSSA, MRSA and MRSE isolated from skin and soft tissue infections and the antibac-
terial activity of ZnO nanoparticles. World J Microbiol Biotechnol. 2012;28(4):1605–13.
[54] Meghana S, Kabra P, Chakraborty S, Padmavathy N. Understanding the pathway of 
antibacterial activity of copper oxide nanoparticles. RSC Adv. 2015;5(16):12293–9.
[55] Hans M, Erbe A, Mathews S, Chen Y, Solioz M, Mücklich F. Role of copper oxides in 
contact killing of bacteria. Langmuir. 2013;29(52):16160–6.
[56] Schairer DO, Chouake JS, Nosanchuk JD, Friedman AJ. The potential of nitric oxide 
releasing therapies as antimicrobial agents. Virulence. 2012;3(3):271–9.
[57] Allahverdiyev AM, Abamor ES, Bagirova M, Rafailovich M. Antimicrobial effects of 
TiO
2
 and Ag
2
O nanoparticles against drug-resistant bacteria and leishmania parasites. 
Future Microbiol. 2011;6(8):933–40.
[58] Ansari MA, Khan HM, Khan AA, Pal R, Cameotra SS. Antibacterial potential of Al
2
O
3
 
nanoparticles against multidrug resistance strains of Staphylococcus aureus isolated 
from skin exudates. J Nanoparticle Res. 2013;15(10):1970–1982.
[59] Ismail RA, Sulaiman GM, Abdulrahman SA, Marzoog TR. Antibacterial activity of mag-
netic iron oxide nanoparticles synthesized by laser ablation in liquid. Mater Sci Eng C. 
2015;53:286–97.
[60] Pelletier DA, Suresh AK, Holton GA, McKeown CK, Wang W, Gu B, et al. Effects of 
engineered cerium oxide nanoparticles on bacterial growth and viability. Appl Environ 
Microbiol. 2010;76(24):7981–9.
[61] Lemire JA, Harrison JJ, Turner RJ. Antimicrobial activity of metals: mechanisms, molec-
ular targets and applications. Nat Rev Microbiol. 2013;11(6):371–84.
[62] R K, Pv K. Dendrimeric biocides—a tool for effective antimicrobial therapy. J Nanomed 
Nanotechnol. 2016;07(02).
[63] Beyth N, Yudovin-Farber I, Bahir R, Domb AJ, Weiss EI. Antibacterial activity of dental 
composites containing quaternary ammonium polyethylenimine nanoparticles against 
Streptococcus mutans. Biomaterials. 2006;27(21):3995–4002.
Antibacterial Agents80
[64] Beyth N, Houri-Haddad Y, Baraness-Hadar L, Yudovin-Farber I, Domb AJ, Weiss EI. 
Surface antimicrobial activity and biocompatibility of incorporated polyethylenimine 
nanoparticles. Biomaterials. 2008;29(31):4157–63.
[65] Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan 
nanoparticles. Carbohydr Res. 2004;339(16):2693–700.
[66] Gazit E. Self-assembled peptide nanostructures: the design of molecular building blocks 
and their technological utilization. Chem Soc Rev. 2007;36(8):1263.
[67] Lyon DY, Adams LK, Falkner JC, Alvarez PJJ. Antibacterial activity of fullerene water 
suspensions: effects of preparation method and particle size. Environ Sci Technol. 
2006;40(14):4360–6.
[68] Kang S, Pinault M, Pfefferle LD, Elimelech M. Single-walled carbon nanotubes exhibit 
strong antimicrobial activity. Langmuir. 2007;23(17):8670–3.
[69] Choi J, Seo Y, Hwang J, Kim J, Jeong Y, Hwang M. Antibacterial activity and cyto-
toxicity of multi-walled carbon nanotubes decorated with silver nanoparticles. Int J 
Nanomedicine. 2014;4621.
[70] Li Q, Mahendra S, Lyon DY, Brunet L, Liga MV, Li D, et al. Antimicrobial nanomateri-
als for water disinfection and microbial control: potential applications and implications. 
Water Res. 2008;42(18):4591–602.
[71] Lam SJ, O’Brien-Simpson NM, Pantarat N, Sulistio A, Wong EHH, Chen Y-Y, et al. 
Combating multidrug-resistant Gram-negative bacteria with structurally nanoengi-
neered antimicrobial peptide polymers. Nat Microbiol. 2016;1(11):16162.
[72] Wu R, Zhang H, Pan J, Zhu H, Ma Y, Cui W, et al. Spatio-design of multidimensional 
prickly Zn-doped CuO nanoparticle for efficient bacterial killing. Adv Mater Interfaces. 
2016;3(18):1600472.
[73] Smekalova M, Aragon V, Panacek A, Prucek R, Zboril R, Kvitek L. Enhanced antibacte-
rial effect of antibiotics in combination with silver nanoparticles against animal patho-
gens. Vet J. 2016;209:174–9.
[74] Li P, Li J, Wu C, Wu Q, Li J. Synergistic antibacterial effects of β-lactam antibiotic com-
bined with silver nanoparticles. Nanotechnology. 2005;16(9):1912–7.
[75] Huh AJ, Kwon YJ. “Nanoantibiotics”: a new paradigm for treating infectious diseases 
using nanomaterials in the antibiotics resistant era. J Controlled Release. 2011;156(2): 
128–45.
[76] Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial 
 activity: a review. J Pharm Anal. 2016;6(2):71–9.
[77] Jacqueline C, Caillon J. Impact of bacterial biofilm on the treatment of prosthetic joint 
infections. J Antimicrob Chemother. 2014;69(suppl 1):i37–40.
[78] Malone M, Goeres DM, Gosbell I, Vickery K, Jensen S, Stoodley P. Approaches to bio-
film-associated infections: the need for standardized and relevant biofilm methods for 
clinical applications. Expert Rev Anti Infect Ther. 2017;15(2):147–56.
Current Approaches for Exploration of Nanoparticles as Antibacterial Agents
http://dx.doi.org/10.5772/68138
81
[79] Lebeaux D, Chauhan A, Rendueles O, Beloin C. From in vitro to in vivo models of bacte-
rial biofilm-related infections. Pathogens. 2013;2(2):288–356.
[80] Govan JRW. Multidrug-resistant pulmonary infection in cystic fibrosis—what does 
“resistant” mean? J Med Microbiol. 2006;55(12):1615–7.
[81] Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Che-
mother. 2001;48(suppl 1):5–16.
[82] Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical prac-
tice guidelines for the diagnosis and management of intravascular catheter-related 
infection: 2009 update by the infectious diseases society of America. Clin Infect Dis. 
2009;49(1):1–45.
[83] Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mecha-
nisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis. 
2004;38(6):864–70.
[84] Weir E, Lawlor A, Whelan A, Regan F. The use of nanoparticles in anti-microbial materi-
als and their characterization. The Analyst. 2008;133(7):835.
[85] Nostro A, Procopio F, Pizzimenti FC, Cannatelli MA, Bisignano G, Marino A, et al. 
Effects of oregano, carvacrol and thymol on Staphylococcus aureus and Staphylococcus epi-
dermidis biofilms. J Med Microbiol. 2007;56(4):519–23.
[86] Macia MD, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-
growing bacteria. Clin Microbiol Infect. 2014;20(10):981–90.
[87] LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions 
on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant. 
2007;22(8):2239–46.
[88] Ali L, Khambaty F, Diachenko G. Investigating the suitability of the Calgary Biofilm 
Device for assessing the antimicrobial efficacy of new agents. Bioresour Technol. 2006; 
97(15):1887–93.
[89] Coenye T, Nelis HJ. In vitro and in vivo model systems to study microbial biofilm forma-
tion. J Microbiol Methods. 2010;83(2):89–105.
[90] Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. A modified microtiter-
plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods. 
2000;40(2):175–9.
[91] Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of 
microbial biofilms grown in microtiter plates. J Microbiol Methods. 2008;72(2):157–65.
[92] Junker LM, Clardy J. High-throughput screens for small-molecule inhibitors of pseu-
domonas aeruginosa biofilm development. Antimicrob Agents Chemother. 2007;51(10): 
3582–90.
Antibacterial Agents82
[93] Pantanella F, Valenti P, Natalizi T. Analytical techniques to study microbial biofilm on 
abiotic surfaces: pros and cons of the main techniques currently in use. Ann Ig Med 
Prev E Comunità. 2013;25(1):31–42.
[94] Pitts B, Hamilton MA, Zelver N, Stewart PS. A microtiter-plate screening method for 
biofilm disinfection and removal. J Microbiol Methods. 2003;54(2):269–76.
[95] O’Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011;47:2437.
[96] Van den Driessche F, Rigole P, Brackman G, Coenye T. Optimization of resazurin-
based viability staining for quantification of microbial biofilms. J Microbiol Methods. 
2014;98:31–4.
[97] Mariscal A, Lopez-Gigosos RM, Carnero-Varo M, Fernandez-Crehuet J. Fluorescent 
assay based on resazurin for detection of activity of disinfectants against bacterial bio-
film. Appl Microbiol Biotechnol. 2009;82(4):773–83.
[98] Sandberg ME, Schellmann D, Brunhofer G, Erker T, Busygin I, Leino R, et al. Pros and 
cons of using resazurin staining for quantification of viable Staphylococcus aureus bio-
films in a screening assay. J Microbiol Methods. 2009;78(1):104–6.
[99] Hannig C, Follo M, Hellwig E, Al-Ahmad A. Visualization of adherent micro-organ-
isms using different techniques. J Med Microbiol. 2010;59(1):1–7.
[100] Manavathu EK, Vager DL, Vazquez JA. Development and antimicrobial susceptibility 
studies of in vitro monomicrobial and polymicrobial biofilm models with Aspergillus 
fumigatus and Pseudomonas aeruginosa. BMC Microbiol. 2014;14(1):53.
[101] Viganor L, Galdino ACM, Nunes APF, Santos KRN, Branquinha MH, Devereux M, et 
al. Anti-Pseudomonas aeruginosa activity of 1,10-phenanthroline-based drugs against 
both planktonic- and biofilm-growing cells. J Antimicrob Chemother. 2016;71(1):128–34.
[102] Webster TJ, Seil I. Antimicrobial applications of nanotechnology: methods and litera-
ture. Int J Nanomedicine. 2012;2767.
[103] Manner S, Skogman M, Goeres D, Vuorela P, Fallarero A. Systematic exploration of 
natural and synthetic flavonoids for the inhibition of Staphylococcus aureus biofilms. Int 
J Mol Sci. 2013;14(10):19434–51.
[104] Toté K, Berghe DV, Maes L, Cos P. A new colorimetric microtitre model for the detec-
tion of Staphylococcus aureus biofilms: new S. aureus biofilm model. Lett Appl Microbiol. 
2007;46(2):249–54.
[105] ISO/TS 16550:2014 Determination of silver nanoparticles potency by release of muramic 
acid from Staphylococcus aureus. British Standards Institution; 2014.
[106] Kim JS, Kuk E, Yu KN, Kim J-H, Park SJ, Lee HJ, et al. Antimicrobial effects of silver 
nanoparticles. Nanomedicine Nanotechnol Biol Med. 2007;3(1):95–101.
[107] Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on 
E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci. 2004;275(1):177–82.
Current Approaches for Exploration of Nanoparticles as Antibacterial Agents
http://dx.doi.org/10.5772/68138
83
[108] Cremonini E, Zonaro E, Donini M, Lampis S, Boaretti M, Dusi S, et al. Biogenic sele-
nium nanoparticles: characterization, antimicrobial activity and effects on human den-
dritic cells and fibroblasts. Microb Biotechnol. 2016;9(6):758–71.
[109] Sodagar A, Akhavan A, Hashemi E, Arab S, Pourhajibagher M, Sodagar K, et al. 
Evaluation of the antibacterial activity of a conventional orthodontic composite con-
taining silver/hydroxyapatite nanoparticles. Prog Orthod. 2016;17(1).
[110] Díez-Martínez R, García-Fernández E, Manzano M, Martínez Á, Domenech M, Vallet-
Regí M, et al. Auranofin-loaded nanoparticles as a new therapeutic tool to fight strepto-
coccal infections. Sci Rep. 2016;6:19525.
[111] Takahashi C, Akachi Y, Ogawa N, Moriguchi K, Asaka T, Tanemura M, et al. Morphologi-
cal study of efficacy of clarithromycin-loaded nanocarriers for treatment of biofilm infec-
tion disease. Med Mol Morphol. 2016;50(1):9–16.
[112] Barros J, Grenho L, Fontenente S, Manuel CM, Nunes OC, Melo LF, et al. Staphylococcus 
aureus and Escherichia coli dual-species biofilms on nanohydroxyapatite loaded with 
CHX or ZnO nanoparticles: DUAL-SPECIES BIOFILMS ON NANOHA-CHX OR 
NANOHA-ZNO. J Biomed Mater Res A. 2017;105(2):491–497.
[113] Khan ST, Ahmad J, Ahamed M, Musarrat J, Al-Khedhairy AA. Zinc oxide and titanium 
dioxide nanoparticles induce oxidative stress, inhibit growth, and attenuate biofilm for-
mation activity of Streptococcus mitis. JBIC J Biol Inorg Chem. 2016;21(3):295–303.
[114] Krausz AE, Adler BL, Cabral V, Navati M, Doerner J, Charafeddine RA, et al. Curcumin-
encapsulated nanoparticles as innovative antimicrobial and wound healing agent. 
Nanomed Nanotechnol Biol Med. 2015;11(1):195–206.
[115] Wu J, Xu H, Tang W, Kopelman R, Philbert MA, Xi C. Eradication of bacteria in suspen-
sion and biofilms using methylene blue-loaded dynamic nanoplatforms. Antimicrob 
Agents Chemother. 2009;53(7):3042–3048.
[116] Du J, Singh H, Yi T-H. Antibacterial, anti-biofilm and anticancer potentials of green 
 synthesized silver nanoparticles using benzoin gum (Styrax benzoin) extract. Bioprocess 
Biosyst Eng. 2016;39(12):1923–1931.
[117] Krishnamoorthy K, Manivannan G, Kim SJ, Jeyasubramanian K, Premanathan M. 
Antibacterial activity of MgO nanoparticles based on lipid peroxidation by oxygen 
vacancy. J Nanoparticle Res. 2012;14(9).
[118] Flores CY, Miñán AG, Grillo CA, Salvarezza RC, Vericat C, Schilardi PL. Citrate-capped 
silver nanoparticles showing good bactericidal effect against both planktonic and ses-
sile bacteria and a low cytotoxicity to osteoblastic cells. ACS Appl Mater Interfaces. 
2013;5(8):3149–59.
[119] Ramasamy M, Lee J-H, Lee J. Potent antimicrobial and antibiofilm activities of bacte-
riogenically synthesized gold-silver nanoparticles against pathogenic bacteria and their 
physiochemical characterizations. J Biomater Appl. 2016;31(3):366–78.
Antibacterial Agents84
[120] Liakos I, Grumezescu A, Holban A, Florin I, D’Autilia F, Carzino R, et al. Polylactic acid—
lemongrass essential oil nanocapsules with antimicrobial properties. Pharmaceuticals. 
2016;9(3):42.
[121] Vijayakumar S, Vaseeharan B, Malaikozhundan B, Shobiya M. Laurus nobilis leaf 
extract mediated green synthesis of ZnO nanoparticles: characterization and biomedi-
cal applications. Biomed Pharmacother. 2016;84:1213–22.
[122] Manju S, Malaikozhundan B, Vijayakumar S, Shanthi S, Jaishabanu A, Ekambaram P, et 
al. Antibacterial, antibiofilm and cytotoxic effects of Nigella sativa essential oil coated 
gold nanoparticles. Microb Pathog. 2016;91:129–35.
[123] Konwar A, Kalita S, Kotoky J, Chowdhury D. Chitosan–iron oxide coated graphene 
oxide nanocomposite hydrogel: a robust and soft antimicrobial biofilm. ACS Appl 
Mater Interfaces. 2016;8(32):20625–20634.
[124] Cihalova K, Chudobova D, Michalek P, Moulick A, Guran R, Kopel P, et al. Staphylococcus 
aureus and MRSA growth and biofilm formation after treatment with antibiotics and 
SeNPs. Int J Mol Sci. 2015;16(10):24656–24672.
[125] Ramalingam V, Rajaram R, PremKumar C, Santhanam P, Dhinesh P, Vinothkumar S, et 
al. Biosynthesis of silver nanoparticles from deep sea bacterium Pseudomonas aeruginosa 
JQ989348 for antimicrobial, antibiofilm, and cytotoxic activity: biosynthesis of silver 
nanoparticles. J Basic Microbiol. 2014;54(9):928–36.
[126] Kalishwaralal K, BarathManiKanth S, Pandian SRK, Deepak V, Gurunathan S. 
Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and 
Staphylococcus epidermidis. Colloids Surf B Biointerfaces. 2010;79(2):340–344.
[127] Akhil K, Jayakumar J, Gayathri G, Khan SS. Effect of various capping agents on pho-
tocatalytic, antibacterial and antibiofilm activities of ZnO nano particles. J Photochem 
Photobiol B. 2016;160:32–42.
[128] Sonkusre P, Singh Cameotra S. Biogenic selenium nanoparticles inhibit Staphylococcus 
aureus adherence on different surfaces. Colloids Surf B Biointerfaces. 2015;136:1051–1057.
[129] Aliasghari A, Rabbani Khorasgani M, Vaezifar S, Rahimi F, Younesi H, Khoroushi M. 
Evaluation of antibacterial efficiency of chitosan and chitosan nanoparticles on cario-
genic streptococci: an in vitro study. Iran J Microbiol. 2016;8(2):93–100.
[130] Yeroslavsky G, Lavi R, Alishaev A, Rahimipour S. Sonochemically-produced metal-
containing polydopamine nanoparticles and their antibacterial and antibiofilm activity. 
Langmuir. 2016;32(20):5201–12.
[131] Ahmed A, Khan AK, Anwar A, Ali SA, Shah MR. Biofilm inhibitory effect of chlorhexi-
dine conjugated gold nanoparticles against Klebsiella pneumoniae. Microb Pathog. 
2016;98:50–56.
[132] Shi S, Jia J, Guo X, Zhao Y, Chen D, Guo Y, et al. Reduced Staphylococcus aureus biofilm 
formation in the presence of chitosan-coated iron oxide nanoparticles. Int J Nanomed. 
2016;11:6499–6506.
Current Approaches for Exploration of Nanoparticles as Antibacterial Agents
http://dx.doi.org/10.5772/68138
85
[133] Fazly Bazzaz BS, Khameneh B, Zarei H, Golmohammadzadeh S. Antibacterial efficacy 
of rifampin loaded solid lipid nanoparticles against Staphylococcus epidermidis biofilm. 
Microb Pathog. 2016;93:137–144.
[134] Giri K, Rivas Yepes L, Duncan B, Kolumam Parameswaran P, Yan B, Jiang Y, et al. 
Targeting bacterial biofilms via surface engineering of gold nanoparticles. RSC Adv. 
2015;5(128):105551–105559.
[135] Boda SK, Broda J, Schiefer F, Weber-Heynemann J, Hoss M, Simon U, et al. Cytotoxicity 
of ultrasmall gold nanoparticles on planktonic and biofilm encapsulated gram-positive 
Staphylococci. Small. 2015;11(26):3183–3193.
[136] Skogman ME, Vuorela PM, Fallarero A. Combining biofilm matrix measurements with 
biomass and viability assays in susceptibility assessments of antimicrobials against 
Staphylococcus aureus biofilms. J Antibiot (Tokyo). 2012;65(9):453–459.
[137] Wirth SM, Lowry GV, Tilton RD. Natural organic matter alters biofilm tolerance to 
silver nanoparticles and dissolved silver. Environ Sci Technol. 2012;46(22):12687–12696.
[138] Mu H, Tang J, Liu Q, Sun C, Wang T, Duan J. Potent antibacterial nanoparticles against 
biofilm and intracellular bacteria. Sci Rep. 2016;6:18877.
[139] Loo C-Y, Rohanizadeh R, Young PM, Traini D, Cavaliere R, Whitchurch CB, et al. 
Combination of silver nanoparticles and curcumin nanoparticles for enhanced anti-
biofilm activities. J Agric Food Chem. 2016;64(12):2513–2522.
[140] Niemirowicz K, Piktel E, Wilczewska A, Markiewicz K, Durnaś B, Wątek M, et al. 
Core-shell magnetic nanoparticles display synergistic antibacterial effects against 
Pseudomonas aeruginosa and Staphylococcus aureus when combined with cathelicidin 
LL-37 or selected ceragenins. Int J Nanomed. 2016;11:5443–55.
[141] Ionescu AC, Brambilla E, Travan A, Marsich E, Donati I, Gobbi P, et al. Silver– 
polysaccharide antimicrobial nanocomposite coating for methacrylic surfaces reduces 
Streptococcus mutans biofilm formation in vitro. J Dent. 2015;43(12):1483–1490.
[142] Gahlawat G, Shikha S, Chaddha BS, Chaudhuri SR, Mayilraj S, Choudhury AR. Microbial 
glycolipoprotein-capped silver nanoparticles as emerging antibacterial agents against 
cholera. Microb Cell Factories. 2016;15:25.
[143] Suppi S, Kasemets K, Ivask A, Künnis-Beres K, Sihtmäe M, Kurvet I, et al. A novel 
method for comparison of biocidal properties of nanomaterials to bacteria, yeasts and 
algae. J Hazard Mater. 2015;286:75–84.
[144] Kar S. Development of nano mullite based mesoporous silica biocer with incorporated 
bacteria for arsenic remediation. Ceram Silik. 2016;60(3):1–10.
Antibacterial Agents86
